High Cholesterol

High cholesterol - everybody talks about it, 37 million American adults have high blood cholesterol levels, and 105 million have cholesterol levels that are higher than desirable (hypercholesterolemia). It is a deadly killer with NO visible symptoms. Find out what you need to do about it NOW so you don't become one of its victims.



When the levels of cholesterol in your bloodstream become too high, your likelihood of developing fatty deposits called plaques in your blood vessels increases. Over time, these plaques start to block your arteries, which impedes blood flow and creates a condition called atherosclerosis. Narrowing of the arteries that supply your heart with blood (coronary artery disease) can stop your heart muscles from getting enough blood , causing an increased risk of a heart attack. Similarly, a decreased blood flow to your brain can cause a stroke. Less blood flowing to your lower limbs can result in exercise-related pain or even gangrene.

Fortunately there are steps you can take today to start reducing your cholesterol levels - find out what changes you can make to your lifestyle or diet that can help bring your cholesterol levels down and improve your health. It has been estimated that a 10 percent reduction in cholesterol levels throughout the U.S. population would bring the rate of heart disease down by 30 percent.

Cholesterol News From Medical News Today

Latest Cholesterol News From Medical News Today.

Transporting Your Apolipoproteins Testing To The Next Level

Randox produces high quality apolipoprotein tests for the diagnosis, monitoring and research of cardiovascular disease and related conditions. Apolipoproteins are essential components of lipoproteins, for example HDL and LDL, responsible for transporting cholesterol and triglycerides around the body. Six apolipoprotein tests are available from Randox: Apo A-I, Apo A-II, Apo B, Apo C-II, Apo C-III and Apo E.

LifeCycle Pharma Announces Positive Data From LCP-AtorFen Phase II Clinical Program

LifeCycle Pharma A/S (OMX:LCP) announced positive results from the company's Phase II clinical program with LCP-AtorFen, a fixed-dose combination product of atorvastatin and fenofibrate for the treatment of mixed dyslipidemia. LCP-AtorFen is a convenient single tablet with a once-daily dosage profile and is without food effect. "The Phase II clinical program confirmed that LCP-AtorFen was safe and well-tolerated.

Sorting Of CEA Modulated By Cholesterol, Implications For Inflammatory Bowel Disease

In polarized Caco-2 cells, cholesterol was depleted by a combination of synthesis inhibition and plasma membrane extraction with complexing agents. This led to an increased sorting of CEA to the basolateral surface. Interestingly, polarity was not significantly affected by this approach. The association of CEA to lipid rafts, cholesterol, and sphingolipid-enriched microdomains was inhibited in parallel.This study, performed by a team led by Dr.

Effects Of Rimonabant On Cardiometabolic Risk Profile Include Loss Of Visceral Fat And Mobilization Of Liver Fat

At a late breaking presentation made on April 29th during the Annual meeting of the European Atherosclerosis Society held in Istanbul, the investigators of ADAGIO-LIPIDS presented the key findings of a one year trial aiming at further studying the effects of rimonabant on several features of HDL and on a comprehensive set of cardiometabolic markers.

Merck Receives Not Approvable Letter From FDA For MK-0524A (ER Niacin/laropiprant)

Merck & Co., Inc. received a Not Approvable action letter from the U.S. Food and Drug Administration (FDA) for the Company's New Drug Application (NDA) for MK-0524A (ER niacin/laropiprant) for the treatment of primary hypercholesterolemia or mixed dyslipidemia. "We plan to meet with the FDA and to submit additional information to enable the agency to further evaluate the benefit/risk profile of MK-0524A," said Peter S. Kim, Ph. D.

Tredaptive Recommended For EU Approval For The Treatment Of Mixed Dyslipidaemia And Primary Hypercholesterolaemia

Merck Sharp & Dohme Limited (MSD) announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended marketing approval for 'Tredaptive'™ (nicotinic acid/laropiprant, MSD) 1000 mg / 20 mg modified-release tablets for the treatment of mixed dyslipidaemia and primary hypercholesterolaemia.

Main Menu